Some papers just make no
sense, especially when they appear in top journals, like Nature.
What's going in editor's mind when they are green-lighting this type of research for publication?
Here is a new example for
such paper. It was recently published in Nature (1). This study comes
from Fiona Powrie's lab in UK. She became well-known for her studies
of experimental colitis model in rats or mice upon adoptive transfer
of naïve T cells (then, in 90's, called CD45RBhi). Her
research is mainly focused on interplay between naïve T cells and
Foxp3+ Tregs in colitis models.
This study is another
variation of this approach.
First, the authors made
an observation that gut associated Tregs express IL-33 receptor,
while few Tregs from spleen or lymph nodes do.
Next, in vitro
test showed that combination of IL-33 and TGFbeta-1 augments de
novo Foxp3+ Treg differentiation (IL-33 alone had no effect).
To assess in vivo
role of IL-33 signaling in Tregs, the authors first generated mixed
bone marrow chimera mice using wild-type and IL-33 receptor-deficient
marrow cells (also called ST2 -/-). Next, colitis was induced by combination of treatment
with Helicobacter hepaticus and anti-IL-10R injection.
Analysis of number of colonic Tregs derived from IL-33
receptor-deficient marrow cells (which can not respond to IL-33) were
reduced 2-fold compared to wild-type Tregs. In addition, IL-33
receptor-deficient Tregs expressed reduced amount of Foxp3 compared
to wild-type Tregs (1000 vs. 800 MFI).
Another set of in vivo
experiments showed that IL-33 receptor-deficient Tregs were less
potent in preventing colitis induction by naïve T cells. At 8 weeks
post transfer, IL-33 receptor-deficient Tregs lost much of Foxp3
expression. Of note, in vitro IL-33 receptor-deficient Tregs
were as potent as wild-type Tregs.
To connect this new
observation with their previous studies about IL-23 and colitis, the
authors showed that IL-23 blocks signaling by IL-33 in Tregs.
Finally, another set of
in vivo adoptive transfer experiments into RAG1/IL-23R double
knockout mice showed that in even in absence of IL-23 signaling in
the host, IL-33 receptor-deficient Tregs were less potent in
preventing colitis induction.
The data in Fig. 4d, however, are
difficult to interpret. If IL-23 was blocking Tregs induction solely
through IL-33 inhibition, absence of IL-23 should have had two fold
outcome:
(a) induced much potent
wild-type Tregs and
(b) IL-33
receptor-deficient Tregs should become more potent in preventing
colitis
However, neither outcome
has been observed, that is, in my opinion, very unusual and
unexplainable result and questions the relevance or importance of
all other data.
David